...
Non-white subjects are underrepresented in phase III trials for psoriasis treatments
September 8, 2020

Plaque psoriasis is a common chronic inflammatory skin disease.  Treatment for plaque psoriasis includes oral systemic, topical, and biologic medications. Although biologic therapies continue to be increasingly utilized in treating moderate-to-severe psoriasis, evidence has shown that non-white ethnicity is associated with a reduced likelihood of responding to biologics up to one year in patients with …

...
No increased COVID mortality for plaque psoriasis patients on biologic therapy
July 7, 2020

Biologic treatments have been used to target aberrant immune responses in many diseases including the dermatologic manifestations of psoriasis, systemic lupus erythematosus and atopic dermatitis. The use of biologics is not without hazard as these agents block immune pathways adapted to protect the host. For medical providers who prescribe these agents, there has been concern …

...
Product Theater – Let’s Talk About an Option for Your Patients with Challenging Manifestations of Psoriasis
November 23, 2019

Faculty: Michael Shane Chapman, MD Dr. Michael Chapman presented the afternoon product theater reviewing Otezla (apremilast). Otezla is indicated for the treatment of adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. He mentioned we should approach “psoriasis as a systemic condition …

...
Product Theater – What Sets Taltz Apart
November 22, 2019

Faculty: Jeffrey Johnson, PA-C, DSDPA Physician assistant Jeff Johnson gave an engaging product theater presentation reviewing the medication Taltz Friday morning. Taltz is indicated for adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. It is also indicated for treatment of patients with psoriatic arthritis. Taltz is …

...
Product Theater – Clinical Thoughts on Ilumya™

Faculty: Lindsay S. Ackerman, MD For the Fall Conference afternoon product theater, Dr. Lindsay Ackerman discussed Ilumya for the management of moderate to severe plaque psoriasis.  She reviewed the growth of biologics in the field of psoriasis management since 2004.  Dr. Ackerman encouraged providers to  have a conversation with their patients in order to choose …